Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors
Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate and sunitinib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate
given together with sunitinib in treating patients with gastrointestinal stromal tumors.